HRP20231487T1 - Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona - Google Patents
Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona Download PDFInfo
- Publication number
- HRP20231487T1 HRP20231487T1 HRP20231487TT HRP20231487T HRP20231487T1 HR P20231487 T1 HRP20231487 T1 HR P20231487T1 HR P20231487T T HRP20231487T T HR P20231487TT HR P20231487 T HRP20231487 T HR P20231487T HR P20231487 T1 HRP20231487 T1 HR P20231487T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- lymphoma
- use according
- hematological malignancy
- malignancy
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title claims 17
- 238000000034 method Methods 0.000 title claims 7
- NZYDBVQXOGPDDU-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[[2-fluoro-4-[(3-morpholin-4-ylazetidin-1-yl)methyl]phenyl]methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC1=C(C=C(C=C1)CN1CC(C1)N1CCOCC1)F)=O)=O NZYDBVQXOGPDDU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 206010066476 Haematological malignancy Diseases 0.000 claims 13
- 206010042971 T-cell lymphoma Diseases 0.000 claims 9
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 8
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 7
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 7
- 208000017604 Hodgkin disease Diseases 0.000 claims 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 229940125904 compound 1 Drugs 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Spoj za uporabu u postupku za liječenje hematološke malignosti, naznačen time, da spoj je Spoj 3 predstavljen formulom:
[image]
ili njegov enantiomer, smjesa enantiomera, tautomer, izotopolog, ili njegova farmaceutski prihvatljiva sol, gdje postupak obuhvaća davanje pojedincu kojemu je to potrebno, terapijski učinkovite količine spoja, pri čemu hematološka malignost je limfom marginalne zone (MZL), Burkittov limfom (BL), multipli mijelom (MM), mijelodisplastični sindrom (MDS), akutna mijeloična leukemija (AML), akutna limfocitna leukemija (ALL), T-stanični limfom (TCL), ili Hodgkinov limfom (HL).
2. Spoj za uporabu u postupku za liječenje hematološke malignosti, naznačen time, da spoj je Spoj 1 predstavljen formulom:
[image]
ili njegov tautomer, izotopolog, ili njegova farmaceutski prihvatljiva sol, gdje postupak obuhvaća davanje pojedincu kojemu je to potrebno, terapijski učinkovite količine spoja, pri čemu hematološka malignost je limfom marginalne zone (MZL), Burkittov limfom (BL), multipli mijelom (MM), mijelodisplastični sindrom (MDS), akutna mijeloična leukemija (AML), akutna limfocitna leukemija (ALL), T-stanični limfom (TCL), ili Hodgkinov limfom (HL).
3. Spoj za uporabu u postupku za liječenje hematološke malignosti, naznačen time, da spoj je Spoj 2 predstavljen formulom:
[image]
ili njegov tautomer, izotopolog, ili njegova farmaceutski prihvatljiva sol, gdje postupak obuhvaća davanje pojedincu kojemu je to potrebno, terapijski učinkovite količine spoja, pri čemu hematološka malignost je limfom marginalne zone (MZL), Burkittov limfom (BL), multipli mijelom (MM), mijelodisplastični sindrom (MDS), akutna mijeloična leukemija (AML), akutna limfocitna leukemija (ALL), T-stanični limfom (TCL), ili Hodgkinov limfom (HL).
4. Spoj za uporabu prema patentnom zahtjevu 2, naznačen time, da spoj je Spoj 1 predstavljen formulom:
[image]
5. Spoj za uporabu prema patentnom zahtjevu 2, naznačen time, da spoj je farmaceutski prihvatljiva sol od Spoja 1 predstavljenog formulom:
[image]
6. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je limfom marginalne zone, opcionalno gdje limfom marginalne zone je limfom marginalne zone slezene.
7. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je Burkittov limfom.
8. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je multipli mijelom, opcionalno gdje multipli mijelom je leukemija stanica plazme.
9. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost jesu mijelodisplastični sindromi.
10. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je akutna mijeloična leukemija, opcionalno gdje akutna mijeloična leukemija je B-stanična akutna mijeloična leukemija.
11. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je akutna limfocitna leukemija.
12. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je T-stanični limfom, opcionalno
(i) gdje T-stanični limfom je anaplastični velikostanični limfom; ili
(ii) gdje T-stanični limfom je Sezaryjev sindrom.
13. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da hematološka malignost je Hodgkinov limfom.
14. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da hematološka malignost je ponavljajuća ili uporna.
15. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da hematološka malignost je novodijagnosticirana.
16. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da se spoj primjenjuje oralno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924028P | 2019-10-21 | 2019-10-21 | |
| PCT/US2020/056408 WO2021080935A1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione |
| EP20807558.0A EP4048278B1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231487T1 true HRP20231487T1 (hr) | 2024-03-01 |
Family
ID=73449175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231487TT HRP20231487T1 (hr) | 2019-10-21 | 2020-10-20 | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11666579B2 (hr) |
| EP (1) | EP4048278B1 (hr) |
| JP (1) | JP2022552882A (hr) |
| KR (1) | KR20220103722A (hr) |
| CN (2) | CN115919871A (hr) |
| AU (1) | AU2020372330A1 (hr) |
| BR (1) | BR112022007417A2 (hr) |
| CA (1) | CA3154504A1 (hr) |
| DK (1) | DK4048278T3 (hr) |
| ES (1) | ES2967929T3 (hr) |
| FI (1) | FI4048278T3 (hr) |
| HR (1) | HRP20231487T1 (hr) |
| HU (1) | HUE064768T2 (hr) |
| IL (1) | IL292266A (hr) |
| LT (1) | LT4048278T (hr) |
| MX (1) | MX2022004683A (hr) |
| PL (1) | PL4048278T3 (hr) |
| PT (1) | PT4048278T (hr) |
| RS (1) | RS64936B1 (hr) |
| SI (1) | SI4048278T1 (hr) |
| WO (1) | WO2021080935A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE064768T2 (hu) * | 2019-10-21 | 2024-04-28 | Celgene Corp | Eljárások hematológiai malignitások kezelésére 2-(2,6-dioxopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion alkalmazásával |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3643709T3 (da) * | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Inc | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf |
| PT3784663T (pt) * | 2018-04-23 | 2023-10-10 | Celgene Corp | Compostos de 4-aminoisoindolina-1,3-diona substituídos e o seu uso para tratar linfoma |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| HUE064768T2 (hu) * | 2019-10-21 | 2024-04-28 | Celgene Corp | Eljárások hematológiai malignitások kezelésére 2-(2,6-dioxopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion alkalmazásával |
-
2020
- 2020-10-20 HU HUE20807558A patent/HUE064768T2/hu unknown
- 2020-10-20 PT PT208075580T patent/PT4048278T/pt unknown
- 2020-10-20 ES ES20807558T patent/ES2967929T3/es active Active
- 2020-10-20 CN CN202310078127.4A patent/CN115919871A/zh active Pending
- 2020-10-20 EP EP20807558.0A patent/EP4048278B1/en active Active
- 2020-10-20 AU AU2020372330A patent/AU2020372330A1/en active Pending
- 2020-10-20 RS RS20231119A patent/RS64936B1/sr unknown
- 2020-10-20 HR HRP20231487TT patent/HRP20231487T1/hr unknown
- 2020-10-20 DK DK20807558.0T patent/DK4048278T3/da active
- 2020-10-20 CN CN202080088925.XA patent/CN115087448A/zh active Pending
- 2020-10-20 MX MX2022004683A patent/MX2022004683A/es unknown
- 2020-10-20 JP JP2022523520A patent/JP2022552882A/ja active Pending
- 2020-10-20 PL PL20807558.0T patent/PL4048278T3/pl unknown
- 2020-10-20 US US17/075,523 patent/US11666579B2/en active Active
- 2020-10-20 BR BR112022007417A patent/BR112022007417A2/pt unknown
- 2020-10-20 LT LTEPPCT/US2020/056408T patent/LT4048278T/lt unknown
- 2020-10-20 FI FIEP20807558.0T patent/FI4048278T3/fi active
- 2020-10-20 CA CA3154504A patent/CA3154504A1/en active Pending
- 2020-10-20 WO PCT/US2020/056408 patent/WO2021080935A1/en active Application Filing
- 2020-10-20 KR KR1020227016739A patent/KR20220103722A/ko unknown
- 2020-10-20 SI SI202030324T patent/SI4048278T1/sl unknown
-
2022
- 2022-04-13 IL IL292266A patent/IL292266A/en unknown
-
2023
- 2023-05-10 US US18/315,404 patent/US20230277548A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4048278A1 (en) | 2022-08-31 |
| WO2021080935A1 (en) | 2021-04-29 |
| CN115087448A (zh) | 2022-09-20 |
| RS64936B1 (sr) | 2024-01-31 |
| KR20220103722A (ko) | 2022-07-22 |
| PT4048278T (pt) | 2024-01-12 |
| US20230277548A1 (en) | 2023-09-07 |
| CA3154504A1 (en) | 2021-04-29 |
| ES2967929T3 (es) | 2024-05-06 |
| IL292266A (en) | 2022-06-01 |
| US20210113577A1 (en) | 2021-04-22 |
| HUE064768T2 (hu) | 2024-04-28 |
| PL4048278T3 (pl) | 2024-03-18 |
| FI4048278T3 (fi) | 2023-12-19 |
| AU2020372330A1 (en) | 2022-05-19 |
| US11666579B2 (en) | 2023-06-06 |
| JP2022552882A (ja) | 2022-12-20 |
| LT4048278T (lt) | 2023-12-11 |
| SI4048278T1 (sl) | 2024-01-31 |
| MX2022004683A (es) | 2022-05-10 |
| DK4048278T3 (da) | 2024-01-08 |
| CN115919871A (zh) | 2023-04-07 |
| EP4048278B1 (en) | 2023-11-01 |
| BR112022007417A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528524A5 (hr) | ||
| HRP20170217T1 (hr) | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze | |
| JP2021183609A (ja) | メニン−ｍｌｌの置換された阻害剤及びその使用方法 | |
| JP2019517485A5 (hr) | ||
| Cohen et al. | Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia | |
| JP2020040989A5 (hr) | ||
| US7501412B2 (en) | Isoquinoline compounds and medicinal use thereof | |
| HRP20231487T1 (hr) | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona | |
| HRP20230936T1 (hr) | Kombinirana terapija za liječenje ili prevenciju tumora | |
| JP2019506403A5 (hr) | ||
| FI3500299T3 (fi) | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa | |
| UA84878C2 (ru) | Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения | |
| JP2018524347A5 (hr) | ||
| RU2017133449A (ru) | Кристаллы моноклональных антител к pd-1 человека | |
| MY145465A (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists. | |
| AR045730A1 (es) | Moduladores de lta4h | |
| JP2009518447A5 (hr) | ||
| JP2020506951A5 (hr) | ||
| JP2020531414A5 (hr) | ||
| GEP20084527B (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
| US20060035945A1 (en) | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | |
| RU2009113615A (ru) | Ингибитор киназы | |
| WO2020097400A8 (en) | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof | |
| AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| PE20200741A1 (es) | Composiciones farmaceuticas y metodos para tratar enfermedades cardiovasculares |